Cannabis Council Australia is inviting medical cannabis clinicians and patients to participate in its new survey.
The organisation’s mission is to improve patient outcomes by uniting the industry and boosting Australian market growth and sustainability for growers, manufacturers, suppliers and clinics. The Council envisions an industry supported by the world’s best standards and practices where medicinal cannabis plays a significant role in Australian health, making it a trusted and accessible choice for patients.
The Council is currently running its State of the Industry Survey – 2024, which is part of efforts to gather insights that will help to inform its advocacy work.
There are two pathways on the clinician-led survey – one for clinicians and another for patients. The former will take around 6 minutes to complete, and the latter 3 minutes.
“By participating, you are contributing to a comprehensive understanding of the challenges and successes in the industry, helping us to champion better access, reduce discrimination, and eliminate barriers to care for all involved,” says the Council.
Respondent inputs will be analysed to identify trends, challenges, and opportunities; and findings will be utilised by stakeholders including researchers and policymakers. Those participating will be provided a summary of the survey results.
Survey responses are fully anonymised, meaning no personal identifiers are collected or stored.
“This means that your responses cannot be traced back to you under any circumstances,” states the Council. “The survey has been designed with rigorous privacy safeguards to protect your data, allowing you to provide your insights with complete confidence in the confidentiality of your participation.”
Cannabis Council Australia is a relative newcomer to the Australian organised advocacy space, having only launched this year. While a new kid on the block, the organisation appears to have been quite busy; among its activities have been publishing a position paper on current arrangements for workplace drug testing in the context of legally prescribed medicinal cannabis.
Its growing membership includes firms such as Montu, ANTG, Humacology, Little Green Pharma and Alternaleaf.
Since 2016, there have been more than 1.5 million approvals for cannabis medicines in Australia, however, how many patients that involves isn’t clear as a single patient may be prescribed multiple products under multiple approvals.
